黒色腫の疫学的予測(~2023)

調査会社GlobalData社が発行したリサーチレポート(データ管理コード:GDHCER078-15)
◆英語タイトル:EpiCast Report: Melanoma - Epidemiology Forecast to 2023
◆発行会社/調査会社:GlobalData
◆商品コード:GDHCER078-15
◆発行日:2015年4月6日
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD3,995 ⇒換算¥451,435見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD7,990 ⇒換算¥902,870見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD11,985 ⇒換算¥1,354,305見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[黒色腫の疫学的予測(~2023)]についてメールでお問い合わせはこちら
当調査レポートでは、黒色腫の疫学的市場予測について調査・分析し、以下の構成でお届けいたします。

・イントロダクション
・黒色腫の概要
・リスク要因及び併存症
・主要地域の動向
・疫学的予測方法
・黒色腫の疫学的予測結果(有病率など)
・考察(結論、分析の限界・強み)
*** レポート概要(サマリー)***

EpiCast Report: Melanoma – Epidemiology Forecast to 2023

Summary

Melanoma of the skin is a malignant neoplasm of melanocytes and is a significant source of morbidity and mortality worldwide.

GlobalData epidemiologists forecast that the diagnosed prevalent cases of melanoma of the skin (all ages) in the 8MM will increase from 155,057 diagnosed prevalent cases in 2013 to 207,606 diagnosed prevalent cases in 2023, at an Annual Growth Rate (AGR) of 3.39%. The forecast shows an increase in the number of diagnosed incident cases of melanoma of the skin in all eight markets with AGRs ranging from 1.37% in Germany to 4.64% in the UK. In 2013, there were 639,165 five-year diagnosed prevalent cases of melanoma of the skin in the 8MM. GlobalData epidemiologists forecast that the five-year diagnosed prevalent cases of melanoma of the skin in the 8MM will increase to 860,889 diagnosed prevalent cases by 2023.

This forecast is based on a thorough literature review and is supported by 10 years of historical data from IARC’s CI-5Plus database. The forecast for melanoma incident rates and diagnosed incident cases was based on detailed age-specific and sex-specific incidence trends in each of the 8MM from the CI-5Plus database published by the IARC of the WHO. GlobalData epidemiologists maintained consistent disease definition and forecasting methodology across all 8MM included in the report. In addition, GlobalData epidemiologists provided a comprehensive review of disease statistics and a realistic trend based on insights gained through research and analysis. GlobalData epidemiologists compared the diagnosed incident case estimates for melanoma from this forecast with the number of estimated incident cases from IARC’s GLOBOCAN 2012 to assess the validity of GlobalData’s epidemiological forecast and found the two to be in accordance.

Scope

- The Melanoma EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for melanoma of the skin in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Australia). It includes a 10-year epidemiological forecast for the diagnosed incident cases of melanoma of the skin, segmented by age (in 10-year age groups, beginning at 20 years and ending at =80 years), sex, and cancer stage at diagnosis (American Joint Commission on Cancer [AJCC] stages I, II, III, and IV). The forecast also includes a 10-year epidemiological forecast for the five-year diagnosed prevalent cases and the five-year diagnosed prevalent cases segmented by genetic aberrations (BRAF and c-KIT) in these markets.
- The melanoma epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global melanoma market.
- Quantify patient populations in the global melanoma market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for melanoma therapeutics in each of the markets covered.

*** レポート目次(コンテンツ)***

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 9
3 Epidemiology 10
3.1 Disease Background 10
3.2 Risk Factors and Comorbidities 11
3.3 Global Trends 13
3.3.1 US 14
3.3.2 5EU 14
3.3.3 Japan and Australia 14
3.4 Forecast Methodology 15
3.4.1 Sources Used 17
3.4.2 Sources Not Used 22
3.4.3 Forecast Assumptions and Methods 22
3.5 Epidemiological Forecast for Melanoma (2013-2023) 26
3.5.1 Diagnosed Incident Cases of Melanoma 26
3.5.2 Age-Specific Diagnosed Incident Cases of Melanoma 27
3.5.3 Sex-Specific Diagnosed Incident Cases of Melanoma Skin Cancer 29
3.5.4 Age-Standardized Diagnosed Incidence Rates 31
3.5.5 Pathological Stage at Diagnosis 33
3.5.6 Five-Year Diagnosed Prevalent Cases of Melanoma Skin Cancer 34
3.5.7 Five-Year Diagnosed Prevalent Cases of Melanoma Skin Cancer by Genetic Aberrations 36
3.6 Discussion 38
3.6.1 Epidemiological Forecast Insight 38
3.6.2 Limitations of the Analysis 39
3.6.3 Strengths of the Analysis 40
4 Appendix 41
4.1 Bibliography 41
4.2 About the Authors 46
4.2.1 Epidemiologists 46
4.2.2 Reviewers 46
4.2.3 Global Director of Therapy Analysis and Epidemiology 48
4.2.4 Global Head of Healthcare 48
4.3 About GlobalData 49
4.4 About EpiCast 49
4.5 Disclaimer 50

1.1 List of Tables
Table 1: Risk Factors and Comorbidities for Melanoma of the Skin 12
Table 2: Melanoma of the Skin Staging Definition Equivalencies 16
Table 3: 8MM, Sources of Melanoma of the Skin Incidence Data 17
Table 4: 8MM, Sources of Melanoma of the Skin Incident Cases by Pathological Stage at Diagnosis Data 18
Table 5: 8MM, Sources of Melanoma of the Skin Five-Year Diagnosed Prevalent Cases by Stage Data 19
Table 6: 8MM, Sources of Melanoma of the Skin Diagnosed Prevalent Cases by Genetic Aberration 19
Table 7: 8MM, Diagnosed Incident Cases of Melanoma of the Skin, Both Sexes, Ages ≥20 Years, N, Select Years 2013-2023 26
Table 8: 8MM, Age-Specific Diagnosed Incident Cases of Melanoma of the Skin, N (Row%), 2013 28
Table 9: 8MM, Sex-Specific Diagnosed Incident Cases of Melanoma of the Skin, Ages ≥20 Years, N (Row %), 2013 30
Table 10: Age-Standardized Diagnosed Incidence Rate (ASR) of Melanoma of the Skin, Men and Women, Ages ≥20 Years, 2013 32
Table 11: 8MM, Five-Year Diagnosed Prevalent Cases of Melanoma of the Skin, Both Sexes, ≥20 years, N, Select Years 2013-2023 35

1.2 List of Figures
Figure 1: 8MM, Diagnosed Incident Cases of Melanoma of the Skin, Ages ≥20 Years, Both Sexes, N, 2013-2023 27
Figure 2: Age-Specific Diagnosed Incident Cases of Melanoma of the Skin, Both Sexes, N, 2013 29
Figure 3: Sex-Specific Diagnosed Incident Cases of Melanoma of the Skin (N), 2013 31
Figure 4 : Age-Standardized Diagnosed Incidence Rate (ASR) of Melanoma of the Skin, Men and Women, Ages ≥20 Years, 2013 32
Figure 5: Distribution of Incident Cases of Melanoma Skin Cancer by Stage at Diagnosis (%) 34
Figure 6: 8MM, Five-Year Diagnosed Prevalent Cases of Melanoma of the Skin, Both Sexes, Ages ≥20 Years, N, 2013-2023 36
Figure 7: Five-Year Diagnosed Prevalent Cases of Melanoma of the Skin with BRAF Mutations, Both Sexes, Ages ≥20 Years, N, 2013 37
Figure 8: Five-Year Diagnosed Prevalent Cases of Melanoma of the Skin with NRAS Mutations, Both Sexes, Ages ≥20 Years, 2013 38

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GDHCER078-15 )"黒色腫の疫学的予測(~2023)" (英文:EpiCast Report: Melanoma - Epidemiology Forecast to 2023)はGlobalData社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。